From GlobeNewswire: 2025-05-10 07:15:00

Late-breaking results from the Phase 3 MAESTRO-NAFLD-1 trial showed that 65% of patients with clinically significant portal hypertension at baseline shifted to lower risk categories after two years of treatment with Rezdiffra. Patients also experienced a significant reduction in liver stiffness, demonstrating the drug’s efficacy in improving liver health. These positive results provide hope for patients with MASH cirrhosis and support ongoing trials to confirm the benefits of Rezdiffra in this high-risk population. Madrigal Pharmaceuticals will host a webcast on May 13 to review the detailed data from the trial.

MASH, also known as NASH, is a severe liver disease that can lead to cirrhosis, liver failure, and liver cancer. Patients who progress to cirrhosis face a significantly higher risk of liver-related mortality. Rezdiffra is a liver-directed medication designed to target the underlying causes of MASH. In a pivotal Phase 3 trial, Rezdiffra achieved primary endpoints of fibrosis improvement and MASH resolution, offering hope for patients with moderate to advanced fibrosis. Safety data from the trial showed that Rezdiffra was well-tolerated, with common side effects including diarrhea and nausea.

Patients considering Rezdiffra should consult with their healthcare provider to discuss potential risks and benefits. The medication is indicated for adults with noncirrhotic MASH with moderate to advanced fibrosis and is taken once daily. Adverse effects may include liver injury and gallbladder problems, so it is important to monitor for signs of hepatotoxicity and seek medical attention if symptoms occur. Additionally, patients should inform their healthcare provider of all medications they are taking to avoid interactions with Rezdiffra.

Madrigal Pharmaceuticals is committed to developing innovative treatments for MASH and providing hope for patients with this serious liver disease. Ongoing trials and research aim to further establish the benefits of Rezdiffra in improving outcomes for patients with MASH cirrhosis and advancing the understanding and treatment of this condition.



Read more at GlobeNewswire: Madrigal Announces New Clinical Data Demonstrating